Abstract
After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer.
| Original language | English |
|---|---|
| Article number | 170066 |
| Journal | European Respiratory Review |
| Volume | 26 |
| Issue number | 146 |
| DOIs | |
| Publication status | Published - 31 Dec 2017 |
| Externally published | Yes |